» Articles » PMID: 36125896

H3.3-G34 Mutations Impair DNA Repair and Promote CGAS/STING-mediated Immune Responses in Pediatric High-grade Glioma Models

Abstract

Pediatric high-grade gliomas (pHGGs) are the leading cause of cancer-related deaths in children in the USA. Sixteen percent of hemispheric pediatric and young adult HGGs encode Gly34Arg/Val substitutions in the histone H3.3 (H3.3-G34R/V). The mechanisms by which H3.3-G34R/V drive malignancy and therapeutic resistance in pHGGs remain unknown. Using a syngeneic, genetically engineered mouse model (GEMM) and human pHGG cells encoding H3.3-G34R, we demonstrate that this mutation led to the downregulation of DNA repair pathways. This resulted in enhanced susceptibility to DNA damage and inhibition of the DNA damage response (DDR). We demonstrate that genetic instability resulting from improper DNA repair in G34R-mutant pHGG led to the accumulation of extrachromosomal DNA, which activated the cyclic GMP-AMP synthase/stimulator of IFN genes (cGAS/STING) pathway, inducing the release of immune-stimulatory cytokines. We treated H3.3-G34R pHGG-bearing mice with a combination of radiotherapy (RT) and DNA damage response inhibitors (DDRi) (i.e., the blood-brain barrier-permeable PARP inhibitor pamiparib and the cell-cycle checkpoint CHK1/2 inhibitor AZD7762), and these combinations resulted in long-term survival for approximately 50% of the mice. Moreover, the addition of a STING agonist (diABZl) enhanced the therapeutic efficacy of these treatments. Long-term survivors developed immunological memory, preventing pHGG growth upon rechallenge. These results demonstrate that DDRi and STING agonists in combination with RT induced immune-mediated therapeutic efficacy in G34-mutant pHGG.

Citing Articles

Genetically Engineered and Implantable Mouse Brain Tumor Models: Characterization by Immunohistochemistry and Flow Cytometry.

Mirji A, Singh G, Mujeeb A, McClellan B, Li Y, Perez M Curr Protoc. 2025; 5(1):e70080.

PMID: 39777911 PMC: 11731892. DOI: 10.1002/cpz1.70080.


A scoping review of diffuse hemispheric glioma, H3 G34-mutant: Epigenetic and molecular profiles, clinicopathology, and treatment avenues.

Tang K, Cesaire M, McDonald T, Cimino P, Castro M, Jackson S Neurooncol Adv. 2025; 6(1):vdae208.

PMID: 39759262 PMC: 11697104. DOI: 10.1093/noajnl/vdae208.


Multifaceted roles of cGAS-STING pathway in the lung cancer: from mechanisms to translation.

Wei M, Li Q, Li S, Wang D, Wang Y PeerJ. 2024; 12:e18559.

PMID: 39588006 PMC: 11587877. DOI: 10.7717/peerj.18559.


Alternative lengthening of telomere-based immortalization renders H3G34R-mutant diffuse hemispheric glioma hypersensitive to PARP inhibitor combination regimens.

Laemmerer A, Lehmann C, Mayr L, Bruckner K, Gabler L, Senfter D Neuro Oncol. 2024; 27(3):811-827.

PMID: 39556024 PMC: 11889718. DOI: 10.1093/neuonc/noae228.


Emerging roles of cancer-associated histone mutations in genomic instabilities.

Yadav P, Jain R, Yadav R Front Cell Dev Biol. 2024; 12:1455572.

PMID: 39439908 PMC: 11494296. DOI: 10.3389/fcell.2024.1455572.


References
1.
Xiong Y, Guo Y, Liu Y, Wang H, Gong W, Liu Y . Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor. Neoplasia. 2020; 22(9):431-440. PMC: 7350150. DOI: 10.1016/j.neo.2020.06.009. View

2.
Graham M, Mellinghoff I . Histone-Mutant Glioma: Molecular Mechanisms, Preclinical Models, and Implications for Therapy. Int J Mol Sci. 2020; 21(19). PMC: 7582376. DOI: 10.3390/ijms21197193. View

3.
Lewis P, Muller M, Koletsky M, Cordero F, Lin S, Banaszynski L . Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science. 2013; 340(6134):857-61. PMC: 3951439. DOI: 10.1126/science.1232245. View

4.
Calinescu A, Nunez F, Koschmann C, Kolb B, Lowenstein P, Castro M . Transposon mediated integration of plasmid DNA into the subventricular zone of neonatal mice to generate novel models of glioblastoma. J Vis Exp. 2015; (96). PMC: 4354658. DOI: 10.3791/52443. View

5.
Bjerke L, Mackay A, Nandhabalan M, Burford A, Jury A, Popov S . Histone H3.3. mutations drive pediatric glioblastoma through upregulation of MYCN. Cancer Discov. 2013; 3(5):512-9. PMC: 3763966. DOI: 10.1158/2159-8290.CD-12-0426. View